Sigma Pharmaceuticals Limited
(ASX:SIP) has recorded an underlying net profit after tax of $59.2 million in its full year results.
Sales revenue grew by 10.2 percent to $3.46 billion from $3.14 billion a year earlier.
Sigma attributed revenue to growth in non-PBS revenue, up 17.8 percent. The company said non-PBS revenue accounts for more than 35 percent of total revenue.
Chief executive officer Mark Hooper said the company is confident it can deliver EBIT growth of at least 5 percent per annum for the next two years.
Sigma will pay an interim dividend of 3 cents, fully franked.
